Brought to you by:
SVS announces election results for new leadership
The Society for Vascular Surgery (SVS) has elected Andres Schanzer, MD, as the incoming vice president and Malachi G. Sheahan III, MD, as the new secretary, revealed during Friday night’s Annual Business Meeting, as part of the 2025 Vascular Annual…
Two-year data show continued clinical improvement with VenoValve
Implantation of the VenoValve (enVVeno Medical) continues to promote stabilization of symptoms in patients with deep venous reflux at two-year follow-up. This is the headline finding of data shared yesterday during Plenary Session 6 at VAM 2025. In the abstract…
The people and devices that put ‘the vascular in vascular’
The people, discoveries, innovations and events that brought the vascular surgery profession to where it is today will form the subject matter for this year’s John Homans Lecture—“Who put the vascular in vascular surgery?”—at VAM 2025. Jerry Goldstone, MD, an…
International Chapter highlights pressing need to document PAD and CLTI prevalence in South Asia
There is an urgent need for epidemiological studies to map out the prevalence of chronic limb-threatening ischemia (CLTI)—and peripheral arterial disease (PAD) in general—in South Asia, attendees of the International Chapter Education Session at VAM 2025 heard yesterday morning. That…
Learn from other fields to enhance your practice, vascular surgeon innovators told
“A lot of solutions to your problems exist in somebody else’s operating room, or somebody else’s cath lab, but you never actually go there.” These were the words of Alan B. Lumsden, MD, of the Houston Methodist Hospital in Houston,…
SVS president will stake ‘reclaiming center’ in VAM 2025 address
One of the singular highlights of VAM 2025—the presidential introduction and address—will take place this morning from 11 a.m.–12 p.m. on Morial CC’s First Floor (Great Hall A), with SVS President Matthew Eagleton, MD, centering his focus on the Society’s…
Transatlantic multicenter experience highlights effectiveness of total endovascular aortic repair with F/BEVAR but 5% risk of major stroke
Staged total endovascular aortic repair (TEAR) utilizing arch branched and thoracoabdominal fenestrated and branched endografts is effective, but identified predictors of morbidity and mortality—including stroke—highlight the importance of individualized risk assessment to optimize outcomes. These are some of the key…
Acellular tissue engineered vessel outperforms AVF in high-risk hemodialysis patients
Results from the CLN-PRO-V007 randomized controlled trial of Humacyte’s acellular tissue engineered vessel (ATEV) are set to be shared today during VAM 2025 Plenary 6 (10–11 a.m., First Floor, Great Hall A), showing several clinical benefits when compared to arteriovenous…
Greenberg Lecture encourages ‘move beyond’ binary aortic disease classification
Sherene Shalhub, MD, set out a new biologically informed framework that “captures the diverse spectrum of arterial fragility and repair outcomes across inherited and acquired aortic disease” during today’s Roy Greenberg Distinguished Lecture on Innovation at VAM 2025. Shalhub, chief…
Impact report finds no major change in balance between CAS and CEA following Medicare expansion
An evaluation of trends in the utilization of carotid artery stenting (CAS) versus carotid endarterectomy (CEA) has found there to be “no major change” to tip the balance following the 2023 US Centers for Medicare and Medicaid Services (CMS) expansion…